Last call! Applications for the AACR-KidneyCAN grants are due TODAY by 1:00 pm ET!

bit.ly/AACR-KidneyCAN…

Get those proposals in! Let's #AccelerateCures for #KidneyCancer !

Any patient w #kidneycancer is welcome to attend our KidneyCancerProgram education symposium in Dallas Sat 4/27! Come learn from my colleagues James Brugarolas Hans Hammers Payal Kapur & many more #kidneycancer experts.
Register here: bit.ly/3VyG4rt
Kidney Cancer KCCure KidneyCAN

Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study:
⭕️Final CLEAR trial results: Lenvatinib+pembrolizumab reduces mortality risk by 21% vs sunitinib in advanced RCC.
⭕️While median OS is similar, the combo’s lower HR & tight 95% CI underscore its robust…

According to the NIH, cancer prevention isn’t just about avoiding the disease—it’s about taking steps to reduce risk. With over 2 million new cancer diagnoses expected in 2024, prevention is key. OVAC advocates for increased funding for early detection.

An update: this event is now open to ALL kidney cancer patients, regardless of where they're receiving treatment- we want these resources to be available to any patient experiencing kidney cancer diagnosis, treatment, or survivorship.
RSVP here: bit.ly/3VyG4rt

KidneyCAN Without the advocacy at the hill - this would have been impossible. Thank you for all that you and the wonderful advocates and patients do for #kidneycancer Let’s keep up the work!

Thank you CDMRP for renewing kidneycancerconsortium.org grant!! UTSW Simmons Cancer Center congrats also to MD Anderson Cancer Center coordinating center and other consortium sites. Wonderful colleagues and collaborators.

Thank you, Rep Josh Gottheimer, for meeting with our team to talk about #AcceleratingCures for #KidneyCancer through robust funding of the CDMRP's #KCRP and the NIH and National Cancer Institute.

Thank you for listening to patients and supporting #Telehealth legislation!

The Renee Maria Saliby #kidneycancer biomarker paper in Cancer Cell is online with a detailed tweetorial: consistent benefit across all subgroups of IO-based therapies over VEGF TKI OncoAlert Dana-Farber Lank Center for Genitourinary Oncology @DanaFarber Yale Cancer Center #WCRM #DANA9

#Teamwork with amazing collaborators

Interested in clinical trials in kidney cancer and how to make a decision ?

Learn from the best !

Naomi Haas Bradley McGregor

Abramson Cancer Ctr. Dana-Farber Lank Center for Genitourinary Oncology @DanaFarber KidneyCAN

Check out the AKCI didactic video YouTube page for the latest lecture by Boyi Gan, PhD on ferroptosis targeting in RCC!

youtube.com/@AcademyofKidn…

Among the many characteristically excellent insights here, cannot help but highlight the call to use the #RenalMedullaryCarcinoma paradigm to accelerate discoveries across rare and common diseases. Kidney Cancer Conquer Cancer, the ASCO Foundation The V Foundation KidneyCAN COA - Chromophobe and Oncocytic Tumor Alliance RMC Alliance

2/ Despite great advances in the trt landscape of RCC, the field still lacks robust predictive biomarkers. The IM151 molecular subtypes were developed using NMF. Our aim was to evaluate the biology and predictive nature of these molecular clusters in the JR101 trial

1/ Thrilled to share that our paper “Impact of RCC molecular subtypes on immunotherapy & targeted therapy outcomes” is now published in Cancer Cell
Collaborative effort co-led w/ Chris Labaki & Tejas Jammihal under Eli Van Allen Sachet Ashok Shukla Toni Choueiri, MD David Braun ‘s mentorship…